Segment, Geographic and Other Revenue Information (Tables)

3 Months Ended

Mar. 29, 2015

Reconciliation of Revenue from Segments to Consolidated



The following table provides selected income statement information by reportable segment:
	Revenues				Earnings^(a)
(MILLIONS OF DOLLARS)	March 29, 2015		March 30, 2014		March 29, 2015			March 30, 2014
Three Months Ended
Reportable Segments:
Global Innovative Pharmaceutical (GIP)	$	3,075	$	3,076	$	1,511		$	1,767
Global Vaccines, Oncology and Consumer Healthcare (VOC)	2,664		2,174		1,464			1,057
Global Established Pharmaceutical (GEP)	5,014		5,990		3,256			4,049
Total reportable segments	10,753		11,240		6,232			6,873
Other business activities^(b)	111		56		(669		)	(667		)
Reconciling Items:
Corporate^(c)	—		—		(1,287		)	(1,200		)
Purchase accounting adjustments^(c)	—		—		(903		)	(1,008		)
Acquisition-related costs^(c)	—		—		(23		)	(30		)
Certain significant items^(d)	—		57		(228		)	(1,016		)
Other unallocated	—		—		(41		)	(105		)
	$	10,864	$	11,353	$	3,082		$	2,847


^(a)	Income from continuing operations before provision for taxes on income.


^(b)	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.


^(c)	For a description, see the “Other Costs and Business Activities” section above.


^(d)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

For Revenues in the first quarter of 2014, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Notes to Consolidated Financial Statements––Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures included in our 2014 Financial Report, which was filed as Exhibit 13 to our 2014 Annual Report on Form 10-K.

For Earnings in the first quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $104 million, (ii) charges for business and legal entity alignment of $101 million and (iii) other charges of $23 million. For additional information, see Note 3 and Note 4.

For Earnings in the first quarter of 2014, certain significant items includes: (i) charges for certain legal matters of $694 million, (ii) certain asset impairments of $114 million, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $134 million, (iv) charges for business and legal entity alignment of $29 million and (v) other charges of $45 million. For additional information, see Note 3 and Note 4.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated



The following table provides selected income statement information by reportable segment:
	Revenues				Earnings^(a)
(MILLIONS OF DOLLARS)	March 29, 2015		March 30, 2014		March 29, 2015			March 30, 2014
Three Months Ended
Reportable Segments:
Global Innovative Pharmaceutical (GIP)	$	3,075	$	3,076	$	1,511		$	1,767
Global Vaccines, Oncology and Consumer Healthcare (VOC)	2,664		2,174		1,464			1,057
Global Established Pharmaceutical (GEP)	5,014		5,990		3,256			4,049
Total reportable segments	10,753		11,240		6,232			6,873
Other business activities^(b)	111		56		(669		)	(667		)
Reconciling Items:
Corporate^(c)	—		—		(1,287		)	(1,200		)
Purchase accounting adjustments^(c)	—		—		(903		)	(1,008		)
Acquisition-related costs^(c)	—		—		(23		)	(30		)
Certain significant items^(d)	—		57		(228		)	(1,016		)
Other unallocated	—		—		(41		)	(105		)
	$	10,864	$	11,353	$	3,082		$	2,847


^(a)	Income from continuing operations before provision for taxes on income.


^(b)	Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.


^(c)	For a description, see the “Other Costs and Business Activities” section above.


^(d)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Schedule of Revenues by Geographic Region



The following table provides revenues by geographic area:
	Three Months Ended
(MILLIONS OF DOLLARS)	March 29, 2015		March 30, 2014		% Change
United States	$	4,433	$	4,275	4
Developed Europe^(a)	2,312		2,795		(17	)
Developed Rest of World^(b)	1,493		1,728		(14	)
Emerging Markets^(c)	2,626		2,555		3
Revenues	$	10,864	$	11,353	(4	)


^(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $1.8 billion in the first quarter of 2015 and $2.2 billion in the first quarter of 2014.


^(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.


^(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.

Schedule of Significant Product Revenues



The following table provides detailed revenue information:
		Three Months Ended
(MILLIONS OF DOLLARS)	Business^(a)	March 29, 2015		March 30, 2014
Biopharmaceutical revenues:
Prevnar family^(b)	V	$	1,306	$	927
Lyrica^(c)	GEP/GIP	1,187		1,150
Enbrel (Outside the U.S. and Canada)	GIP	759		914
Lipitor	GEP	441		457
Viagra^(d)	GEP/GIP	396		374
Zyvox	GEP	271		321
Norvasc	GEP	252		278
Sutent	O	242		268
Premarin family	GEP	232		248
Celebrex	GEP	205		624
Vfend	GEP	182		177
BeneFIX	GIP	173		201
Pristiq	GEP	161		172
Chantix/Champix	GIP	158		147
Genotropin	GIP	138		166
Refacto AF/Xyntha	GIP	120		145
Xalkori	O	111		88
Xalatan/Xalacom	GEP	102		119
Medrol	GEP	101		106
Sulperazon	GEP	98		88
Xeljanz	GIP	96		52
Inlyta	O	95		88
Zoloft	GEP	86		101
Zithromax/Zmax	GEP	86		92
Relpax	GEP	80		87
EpiPen	GEP	76		63
Fragmin	GEP	74		81
Tygacil	GEP	74		74
Effexor	GEP	73		82
Toviaz	GIP	63		63
Revatio	GEP	63		76
Unasyn	GEP	55		46
Neurontin	GEP	55		49
Xanax/Xanax XR	GEP	54		59
Rapamune	GIP	53		88
Cardura	GEP	52		66
Ibrance	O	38		—
Alliance revenues^(e)	GEP/GIP	222		213
All other GIP	GIP	179		196
All other GEP	GEP	1,671		1,894
All other V/O	V/O	63		41
Total biopharmaceutical revenues	GEP/GIP/V/O	9,945		10,479
Other revenues:
Consumer Healthcare	C	808		761
Other^(f)		111		113
Revenues		$	10,864	$	11,353


^(a)	Indicates the business to which the revenues relate. GIP = the Global Innovative Pharmaceutical segment; V = the Global Vaccines

business; O = the Global Oncology business; C = the global Consumer Healthcare business; and GEP = the Global Established Pharmaceutical segment.


^(b)	In the first quarter of 2015, all revenues were composed of Prevnar 13/Prevenar 13. In the first quarter of 2014, revenues were composed of the Prevnar family of products, which included Prevnar 13/Prevenar 13 and, to a much lesser extent, Prevenar (7-valent).


^(c)	Lyrica revenues from all of Europe are included in GEP. All other Lyrica revenues are included in GIP.


^(d)	Viagra revenues from the U.S. and Canada are included in GIP. All other Viagra revenues are included in GEP.


^(e)	Includes Eliquis (GIP), Rebif (GIP), Spiriva (GEP) and Aricept (GEP).


^(f)	Other includes revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and revenues related to our transitional manufacturing and supply agreements with Zoetis.